检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《中华全科医学》2014年第6期859-861,916,共4页Chinese Journal of General Practice
基 金:2012浙江省医药卫生科技计划一般项目(2012kyb143)
摘 要:目的观察血必净干预下急性弥漫性腹膜炎合并全身炎症反应综合征(SIRS)患者外周血单个核细胞(PBMC)Toll样受体TLR2 mRNA和TLR4 mRNA及下游炎症介质TNF-α和IL-6的表达,探讨血必净对SIRS的疗效机制。方法将62例符合纳入标准的患者分为SIRS组(33例)与非SIRS组(29例),另外设立健康平行对照组30例。RT-PCR法检测治疗前后PBMC中TLR2 mRNA和TLR4 mRNA表达变化,及ELISA检测治疗前及治疗的第1、3、5、7天血清炎症介质TNF-α和IL-6的变化,经t检验比较各组间的差异性。结果 33例SIRS患者经血必净干预后PBMC中TLR2 mRNA(0.51±0.14)和TLR4 mRNA(0.62±0.23)及血清TNF-α(36.89±12.23)、IL-6(40.27±30.31)表达均显著下降,且SIRS组降低较非SIRS组差异有统计学意义(P<0.05)。结论急性弥漫性腹膜炎SIRS组TLR2 mRNA和TLR4 mRNA及血清TNF-α、IL-6表达均显著下降且症状减轻,提示血必净在阻断炎症发生发展过程中可能发挥一定的作用。Objective To observe the effect of Xue Bi Jing on toll-like receptor TLR2 mRNA and TLR4 mRNA of periph- eral blood mononuclear cell(PBMC) and inflammatory medium TNF-α and IL-6 in acute diffuse peritonitis patients com- bined with systemic inflammatory response syndrome(SIRS) and to discuss the therapeutic mechanism of Xue Bi Jing on patients combined with SIRS. Methods A study was performed on 62 acute diffuse peritonitis patients in which 33 com- bined with SIRS. Another 30 healthy individuals were served as normal control. The mRNA expression of TLR2 mRNA and TLR4 mRNA was detected by RT-PCR;and that of TNF-α and IL-6 was measured on pre-treatment and the 1,3,5,7 day by ELISA. Results After treatment with Xue Bi Jing, TLR2 mRNA ( 0.51 ± 0. 14 ) and TLR 4 mRNA ( 0.62 ± 0.23 ), TNF-et(36.89 ± 12.23) ,IL-6(40.27 ± 30.31 ) were downregulated markedly in 33 patients combined with SIRS. The down indexes in SIRS group were lower than those in non-SIRS group ( P 0.05 ). Conclusion Patients combined with SIRS,the expression of TLR2 mRNA and TLR4 mRNA, TNF-α, IL-6 decreased markedly, which indicated Xue Bi Jing might play an important role in preventing inflammatory.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.218.131.147